497 related articles for article (PubMed ID: 29460121)
21. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery.
Chan KY; Baun M; de Vries R; van den Bogaerdt AJ; Dirven CM; Danser AH; Jansen-Olesen I; Olesen J; Villalón CM; MaassenVanDenBrink A; Gupta S
Cephalalgia; 2011 Jan; 31(2):181-9. PubMed ID: 20974589
[TBL] [Abstract][Full Text] [Related]
22. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
23. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
24. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
26. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Braas KM; May V; Vizzard MA
J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.
Baun M; Hay-Schmidt A; Edvinsson L; Olesen J; Jansen-Olesen I
Eur J Pharmacol; 2011 Nov; 670(1):186-94. PubMed ID: 21914446
[TBL] [Abstract][Full Text] [Related]
28. Aging-Induced Modulation of Pituitary Adenylate Cyclase-Activating Peptide- and Vasoactive Intestinal Peptide-Induced Vasomotor Responses in the Arteries of Mice.
Ivic I; Solymar M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D
J Vasc Res; 2017; 54(6):359-366. PubMed ID: 29131060
[TBL] [Abstract][Full Text] [Related]
29. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
30. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
31. VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium.
Erdling A; Sheykhzade M; Maddahi A; Bari F; Edvinsson L
Neuropeptides; 2013 Apr; 47(2):85-92. PubMed ID: 23375386
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
33. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
34. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
35. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.
Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT
Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons.
DeHaven WI; Cuevas J
Neurosci Lett; 2002 Aug; 328(1):45-9. PubMed ID: 12123856
[TBL] [Abstract][Full Text] [Related]
37. [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
39. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery.
Boni LJ; Ploug KB; Olesen J; Jansen-Olesen I; Gupta S
Cephalalgia; 2009 Aug; 29(8):837-47. PubMed ID: 19220306
[TBL] [Abstract][Full Text] [Related]
40. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
